These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2201044)

  • 1. Systemic treatment for renal cell carcinoma: an overview.
    Swanson DA
    Prog Clin Biol Res; 1990; 350():201-25. PubMed ID: 2201044
    [No Abstract]   [Full Text] [Related]  

  • 2. Pre-clinical models for immunotherapy of melanoma.
    Reisfeld RA
    Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
    [No Abstract]   [Full Text] [Related]  

  • 3. Active and passive immunotherapy: vaccines and antibodies.
    Oosterwijk E; Divgi C; Bander NH
    BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal cell carcinoma: recent progress and future directions.
    Mulders P; Figlin R; deKernion JB; Wiltrout R; Linehan M; Parkinson D; deWolf W; Belldegrun A
    Cancer Res; 1997 Nov; 57(22):5189-95. PubMed ID: 9371523
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recent management of renal cell carcinoma].
    Nishio Y; Yoshida O
    Gan To Kagaku Ryoho; 1988 Feb; 15(2):219-23. PubMed ID: 3257677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel investigative approaches for advanced renal cell carcinoma.
    Berg WJ; Divgi CR; Nanus DM; Motzer RJ
    Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma.
    Oosterwijk E; Debruyne FM; Schalken JA
    Semin Oncol; 1995 Feb; 22(1):34-41. PubMed ID: 7855618
    [No Abstract]   [Full Text] [Related]  

  • 12. New agents for the treatment of renal cell carcinoma.
    Tian GG; Dawson NA
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):546-54. PubMed ID: 12113087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in chemotherapy for renal cell carcinoma.
    Huben RP
    Semin Urol; 1992 Feb; 10(1):16-22. PubMed ID: 1565899
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proceedings: Current results from treatment of renal cell carcinoma.
    Murphy GP
    Proc Natl Cancer Conf; 1972; 7():751-9. PubMed ID: 4587662
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphocyte therapy of renal cell carcinoma.
    Dillman RO
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeted therapies for renal cell carcinoma.
    Graham SD; Warden ME; Lou J
    Can J Urol; 2007 Dec; 14 Suppl 1():48-52. PubMed ID: 18163945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumor effects of IFN- beta against human renal cell carcinoma in athymic nude mice.
    Shirahama T; Kayajima T; Ohi Y
    In Vivo; 1989; 3(5):345-9. PubMed ID: 2519876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New targets and drugs for treatment of advanced renal cell carcinoma].
    Rohde D
    Aktuelle Urol; 2005 Apr; 36(2):125-30. PubMed ID: 15902572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.